ERBB2 and breast carcinoma: Furthermore, the ongoing DESTINY-Breast05 trial (NCT04622319) is designed to assess DS-8201 versus T-DM1 in patients with HER2-positive primary breast cancer who have residual invasive disease in the breast or axillary lymph nodes and are at a higher risk of recurrence.